The abstract is read at the publisher; the summary is JClub's.
In symptomatic paradoxical low-flow, low-gradient aortic stenosis, TAVR plus optimal medical therapy did not significantly reduce 2-year all-cause mortality versus optimal medical therapy alone (29.0% vs 37.1%).
- Why it matters: Paradoxical low-flow, low-gradient aortic stenosis carries worse outcomes, yet TAVR has not been directly tested against optimal medical therapy alone in a dedicated randomized trial.
- What they did: In a multicenter open-label randomized study, 120 symptomatic patients with pLFLG AS were assigned 2:1 to TAVR plus OMT or OMT alone, with all-cause death assessed 2 years after enrollment of the last patient.
- The result: Mortality at 2 years (HR 0.83; P=0.60) and at 5 years (44.9% vs 56.6%; HR 0.76; P=0.35) was not significantly different, while symptoms improved and first endpoint-related rehospitalizations were lower with TAVR.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.